<DOC>
	<DOC>NCT02163993</DOC>
	<brief_summary>The main purpose of this study is to evaluate whether the study drug known as LY2951742 is safe and effective in the prevention of migraine headaches. The study will last between 28 and 36 weeks.</brief_summary>
	<brief_title>A Study of LY2951742 in Participants With Migraine Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Participants with a history of migraine of at least 1 year prior to enrollment. Migraine onset prior to age 50. Current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF). History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine, and basilartype migraine. Have a history or presence of other medical illness that indicates a medical problem that would preclude study participation. Failure to respond to more than two adequately dosed effective migraine prevention treatments. Evidence of significant active psychiatric disease, in the opinion of the investigator. Women who are pregnant or nursing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>